Reports for APOTEX INC
Company Name APOTEX INC |
||
|---|---|---|
Totals |
||
Shortage reports |
3367 |
|
| Actual shortage: | 219 (7%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 341 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
67 (28%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DASATINIB | 50MG | TABLET | Resolved | 2021-01-08 | 2021-03-17 | 131145 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-03-25 | 132715 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-02-19 | 2021-03-04 | 134430 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-06-17 | 2022-07-19 | 162910 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2022-10-21 | 2022-12-17 | 172360 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2022-12-05 | 2023-03-16 | 177126 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2024-04-19 | 2024-06-21 | 225776 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2017-08-24 | 2017-09-22 | 20281 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2018-01-18 | 2018-02-12 | 36432 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2024-09-27 | 2024-12-20 | 238844 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Actual shortage | 2025-04-10 | 2025-05-01 | 254838 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-04-13 | 2020-05-22 | 111901 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-05-08 | 2020-05-22 | 114285 |
| APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-06-04 | 2020-07-28 | 116533 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2018-03-13 | 2018-07-03 | 42717 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-08-06 | 2020-11-28 | 121891 |
| APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2023-09-07 | 2023-09-15 | 203819 |
| APO-DEFERASIROX (TYPE J) | 360MG | TABLET | Resolved | 2024-07-18 | 2024-08-23 | 233321 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| NAPROXEN SODIUM TABLETS | 220MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71228 |
| PENTOXIFYLLINE SR | 400MG | TABLET (EXTENDED-RELEASE) | Discontinued | 2018-10-23 | 2022-01-27 | 65438 |
| TEMAZEPAM | 15MG | CAPSULE | Discontinued | 2018-10-23 | 2019-01-14 | 65477 |
| TEMAZEPAM | 30MG | CAPSULE | Discontinued | 2018-10-23 | 2019-01-07 | 65482 |
| TIGECYCLINE | 50MG | POWDER FOR SOLUTION | To be discontinued | 2019-06-21 | 2019-06-21 | 87218 |